PHAT vs IRWD vs PTGX vs SUPN vs INVA

For growth investors, Phathom Pharmaceuticals, Inc.

(PHAT) is the stronger pick with 216. 9% revenue growth year-over-year, versus -89. 4% for Protagonist Therapeutics, Inc. (PTGX). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (11. 9x forward), making it the more compelling value choice. Analysts rate Phathom Pharmaceuticals, Inc. (PHAT) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Innoviva, Inc.

(INVA) is the cheapest at 6. 9x versus Ironwood Pharmaceuticals, Inc. at 27. 8x. On forward P/E, Ironwood Pharmaceuticals, Inc. is actually cheaper at 3. 1x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Protagonist Therapeutics, Inc.

(PTGX) delivered a total return of +238. 8%, compared to -65. 0% for Phathom Pharmaceuticals, Inc. (PHAT). Over 10 years, the gap is even starker: PTGX returned +744. 9% versus IRWD's -59. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 13β versus Ironwood Pharmaceuticals, Inc. 's 2. 50β — meaning IRWD is approximately 1881% more volatile than INVA relative to the S&P 500. On balance sheet safety, Protagonist Therapeutics, Inc. (PTGX) carries a lower debt/equity ratio of 2% versus 23% for Innoviva, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Phathom Pharmaceuticals, Inc.

(PHAT) is pulling ahead at 216. 9% versus -89. 4% for Protagonist Therapeutics, Inc. (PTGX). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -151. 5% for Supernus Pharmaceuticals, Inc.. Over a 3-year CAGR, PTGX leads at 20. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus -282. 8% for Protagonist Therapeutics, Inc. — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IRWD leads at 40. 1% versus -343. 6% for PTGX. At the gross margin level — before operating expenses — IRWD leads at 99. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Ironwood Pharmaceuticals, Inc.

(IRWD) trades at 3. 1x forward P/E versus 30. 6x for Protagonist Therapeutics, Inc. — 27. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PHAT: 101. 7% to $24. 67.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Protagonist Therapeutics, Inc.

(PTGX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 25), +744. 9% 10Y return). Ironwood Pharmaceuticals, Inc. (IRWD) carries a higher beta of 2. 50 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PTGX: +744. 9%, IRWD: -59. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PHAT is a small-cap high-growth stock; IRWD is a small-cap quality compounder stock; PTGX is a small-cap quality compounder stock; SUPN is a small-cap quality compounder stock; INVA is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.